Recombinant Human TGF-beta 3 Protein Best Seller
R&D Systems, part of Bio-Techne | Catalog # 243-B3
Key Product Details
Source
Accession #
Structure / Form
Conjugate
Applications
Product Specifications
Source
Ala301-Ser412 (Tyr340Phe)
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
24 kDa, non-reducing conditions
Activity
The ED50 for this effect is 0.0100-0.0400 ng/mL.
Scientific Data Images for Recombinant Human TGF-beta 3 Protein
Equivalent Bioactivity of Sf 21 (baculovirus)-derived and CHO-derived Recombinant Human TGF‑ beta3.
As an alternative, please consider our next generation CHO-drived Recombinant Human TGF‑ beta3 (8420-B3). It has equivalent bioactivity to Sf 21 (baculovirus)-derived Recombinant Human TGF‑ beta3 (Catalog # 243-B3). It combines R&D Systems quality with scalability that allows for a solid supply chain. Both Recombinant Human TGF‑ beta3 proteins are measured by their ability to inhibit the IL-4-dependent proliferation of Ht-2 mouse T cell. (orange, green, respectively).Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 243-B3
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. |
Reconstitution | Reconstitute at 20 μg/mL in sterile 4 mM HCl containing 1 mg/mL human or bovine serum albumin. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 243-B3/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. |
Reconstitution | Reconstitute 2 µg vials at 20 µg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin. Reconstitute 10 µg or larger vials at 50 µg/mL in sterile 4 mM HCl. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: TGF-beta 3
TGF beta3 (transforming growth factor-beta 3) is a member of a TGF-beta superfamily subgroup that is defined by their structural and functional similarities (1-5). TGF-beta 3 and its closely related proteins, TGF-beta 1 and -beta 2, act as cellular switches to regulate immune function, cell proliferation, and epithelial-mesenchymal transition (4, 6, 7). The non-redundant biological effects of TGF-beta 3 include involvement in palatogenesis, chondrogenesis, and pulmonary development (1, 2, 7-9). Human TGF- beta3 cDNA encodes a 412 amino acid (aa) precursor that contains a 20 aa signal peptide and a 392 aa proprotein. The proprotein is processed by a furinlike convertase to generate a 220 aa latencyassociated peptide (LAP) and a 112 aa mature TGF-beta 3 (10, 11). Mature human TGF-beta 3 shows 100%, 99%, and 98% aa identity with mouse/dog/horse, rat, and pig TGF- beta3, respectively. TGF-beta 3 is secreted as a complex with LAP. This latent form of TGF-beta 3 becomes active upon cleavage by plasmin, matrix metalloproteases, thrombospondin-1, and a subset of integrins (12). TGF-beta 3 binds with high affinity to TGF-beta RII, a type II serine/threonine kinase receptor. This receptor then phosphorylates and activates type I serine/threonine kinase receptors, TGF- beta RI or ALK-1, to modulate transcription through Smad phosphorylation (13-15). The divergent biological effects exerted by individual TGF-beta isoforms is dependent upon the recruitment of co-receptors (TGF- beta RIII and endoglin) and the subsequent initiation of Smad-dependent or -independent signaling pathways (14, 16, 17).
References
- Barrio, M.C. et al. (2014) Cells Tissues Organs. [Epub ahead of print; PMID 24861080].
- Doetschman, T. et al. (2012) Genesis 50:59.
- Mittl, P.R. et al. (1996) Protein Sci. 5:1261.
- Sporn, M.B. (2006) Cytokine Growth Factor Rev. 17:3.
- Wahl, S.M. et al. (2006) Immunol. Rev. 213:213.
- Chang, H. et al. (2002) Endocr. Rev. 23:787.
- Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. 267:6982.
- Jin, J.Z. et al. (2014) Dev. Dyn. [Epub ahead of print; PMID 25104574].
- Tang, Q.O. et al. (2009) Expert Opin. Biol Ther. 9:689.
- Derynck, R. et al. (1988) EMBO J. 7:3737.
- Miyazono, K. et al. (1988) J. Biol. Chem. 263:6407.
- Oklu, R. and R. Hesketh (2000) Biochem. J. 352 Pt 3:601.
- Cui, X.M. and C.F. Shuler (2000) Int. J. Dev. Biol. 44:397.
- de Caestecker, M. (2004) Cytokine Growth Factor Rev. 15:1.
- Nakajima, A. et al. (2007) Dev. Dyn. 236:791.
- Iwata, J. et al. (2012) J. Clin. Invest. 122:873.
- Gatza, C.E. et al. (2010) Cell. Signal. 22:1163.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional TGF-beta 3 Products
Product Documents for Recombinant Human TGF-beta 3 Protein
Product Specific Notices for Recombinant Human TGF-beta 3 Protein
For research use only